Harbour BioMed, 22 Strathmore Rd, Ste 355, Natick, MA 01760, US

Alzheon, based in Framingham, MA, is a biotech company focused on developing a groundbreaking oral treatment for Alzheimer's disease. Their lead candidate, ALZ-801 valiltramiprosate, is currently in Phase 3 testing and is the only oral anti-amyloid disease-modifying treatment in development. With a precision medicine approach, Alzheon aims to slow or even stop disease progression, and potentially prevent the onset of clinical symptoms. Their research, spanning nine years, has resulted in a well-tolerated treatment with a favorable safety profile, making it a promising solution for Alzheimer's patients. Founded in 2013 by Martin Tolar, MD, PhD, Alzheon is dedicated to bringing ALZ-801 to market as the first oral disease-modifying treatment for Alzheimer's. The company has received significant funding, including $51 million in grants from the National Institute on Aging, to support their Phase 3 study. With a validated approach and a prominent global Scientific Advisory Board, Alzheon has published nine peer-reviewed scientific publications on key discoveries in Alzheimer's. Their focus on precision medicine and targeting high-risk patients with specific genetic markers demonstrates their commitment to finding a better solution for Alzheimer's disease.Generated from the website

PIC Therapeutics

Abilab LLC

Avenge Bio